Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sorafenib plus dacarbazine in advanced metastatic melanoma
2004-000725-30Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and dacarbazine in melanoma, sponsored by Bayer. Primary endpoint: Overall tumour response rate. Started Feb 2005; status: completed.
02
Drugs
sorafenibdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2004-000725-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000725-30.